Literature DB >> 29474195

Management of Antiretrovirals in Critically Ill Patients: Great Progress But Potential Pitfalls.

Dante A Suffredini1, Jomy M George, Henry Masur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29474195      PMCID： PMC5899008          DOI： 10.1097/CCM.0000000000003048

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  7 in total

1.  Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.

Authors:  F Croce; P Vitello; A Dalla Pria; A Riva; M Galli; S Antinori
Journal:  Int J STD AIDS       Date:  2010-11       Impact factor: 1.359

2.  Update of Survival for Persons With HIV Infection in Denmark.

Authors:  Nicolai Lohse; Niels Obel
Journal:  Ann Intern Med       Date:  2016-11-15       Impact factor: 25.391

3.  Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.

Authors:  Jacqueline Neuhaus; David R Jacobs; Jason V Baker; Alexandra Calmy; Daniel Duprez; Alberto La Rosa; Lewis H Kuller; Sarah L Pett; Matti Ristola; Michael J Ross; Michael G Shlipak; Russell Tracy; James D Neaton
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

4.  Abacavir hypersensitivity reaction.

Authors:  Ross G Hewitt
Journal:  Clin Infect Dis       Date:  2002-03-19       Impact factor: 9.079

5.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

Authors:  S Hetherington; S McGuirk; G Powell; A Cutrell; O Naderer; B Spreen; S Lafon; G Pearce; H Steel
Journal:  Clin Ther       Date:  2001-10       Impact factor: 3.393

6.  Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults.

Authors:  Frederick J Lee; Janaki Amin; Mark Bloch; Sarah L Pett; Debbie Marriott; Andrew Carr
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

7.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Authors:  David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen
Journal:  Lancet       Date:  2017-07-24       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.